Evidence map›Paper›PMID 35055707›Full record

ArticleInternational journal of environmental research and public health2022

Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses.

Vito Carlo Alberto Caponio, Maria Rosaria Lipsi, Francesca Fortunato, Fabio Arena, Lorenzo Lo Muzio

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The "Magnificent Seven" in Oral and Systemic Health against COVID-19.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vito Carlo Alberto CaponioDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0001-5080-5921
Maria Rosaria LipsiMicrobiology and Virology Unit, Policlinico Riuniti Foggia Hospital, 71122 Foggia, Italy.
Francesca FortunatoHygiene Unit, Policlinico Riuniti Foggia Hospital, 71122 Foggia, Italy.ORCID 0000-0003-0665-5385
Fabio ArenaDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Lorenzo Lo MuzioDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0003-4633-4893
University of Foggia · ITOspedali Riuniti di Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To raise awareness about preventive measures in COVID-19 pandemic, even though fully vaccinated. Although recent trials showed high efficacy of vaccines in preventing symptomatic infections, there are some individuals experiencing symptomatic SARS-CoV-2 infection. In this case report, a fully vaccinated young dental practitioner experienced symptomatic SARS-CoV-2 infection 55 days postvaccination with BNT162b2 Pfizer vaccine with evident ageusia. Diagnostic swabs were performed and used for viral genome sequencing. The patient fully recovered 15 days after diagnosis. Loss of smell and taste, together with nasal congestion were the main reported symptoms. The use of personal protective equipment prevented spread of infection in patients and co-workers. With the increase of people being fully vaccinated, it is still necessary to follow infection preventive protocols by correctly applying personal protective equipment. Although high efficacy has been proved, some individuals may still be vulnerable to symptomatic infection and new guidelines and markers should be adopted and investigated to find out patients for whom vaccination may not determine full immunization.

Indexed as

AgeusiaCOVID-19BNT162 VaccineCOVID-19 VaccinesDentistsHumansmRNA VaccinesPandemicsProfessional RoleSARS-CoV-2Vaccines, SyntheticBNT162 VaccineCOVID-19 VaccinesmRNA VaccinesVaccines, SyntheticcoronavirusCOVID-19healthcare workerSARS-CoV-2vaccine

Identifiers

PMID35055707
PMCPMC8775558
OpenAlexW4205140492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.